/INCY
Incyte Corporation
INCY • NASDAQINCY • NASDAQ • Healthcare
$98.86+0.81%+0.79
$98.86+0.81%(+0.79)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
75Bullish
Risk
86Low Risk
Momentum
62Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
91.5%▲0.4pp
Revenue after COGS
Operating
26.1%▲24.2pp
After operating expenses
Net
25.0%▲24.3pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
15.0
Price vs earnings
EV/EBITDA
9.2
Enterprise value
FCF Yield
7.0%
Cash generation
Earnings Yield
6.7%
Inverse of P/E
Capital Efficiency
21
GoAI Quality ScoreStrong
ROEReturn on Equity
24.9%Strong
ROAReturn on Assets
18.5%Strong
ROICReturn on Invested Capital
20.6%Strong
Financial Health
Current RatioHealthy
3.32
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-1.72x
Debt repayment capacity (<3x)
Income QualityStrong
1.10
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Gross Profit | $4.70B | $3.86B | $3.38B | $3.14B | $2.80B |
| Gross Margin | 91.5% | 91.1% | 91.5% | 92.5% | 93.7% |
| Operating Income | $1.34B | $80.14M | $651.77M | $599.56M | $637.54M |
| Net Income | $1.29B | $32.62M | $597.60M | $340.66M | $948.58M |
| Net Margin | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% |
| EPS | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 |
Average Price Target
$108.90▲ 10.2% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Incyte Corporation, the average price target is $108.90, with a high forecast of $135.00 and a low forecast of $84.00. The average price target represents a 10.2% increase from the current price of $98.86.
Highest
$135.00
Average
$108.90
Lowest
$84.00
Rating Distribution
Strong Buy
0
0%
Buy
24
55%
Hold
18
41%
Sell
2
5%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Overweight
2026-02-18RBC Capital● Maintain
Sector Perform
2026-02-11HC Wainwright & Co.● Maintain
Buy
2026-02-11Stifel● Maintain
Buy
2026-02-11Wells Fargo● Maintain
Equal Weight
2026-02-11Piper Sandler● Maintain
Overweight
2026-02-06Barclays● Maintain
Overweight
2026-02-04Wells Fargo▼ Downgrade
Overweight→Equal Weight
2026-01-20TD Cowen● Maintain
Buy
2026-01-13Morgan Stanley● Maintain
Equal Weight
2026-01-06Earnings History & Surprises
BEAT RATE
44%
Last 18 quarters
AVG SURPRISE
-21.0%
EPS vs Estimate
BEATS / MISSES
8/10
Last 18 quarters
LATEST EPS
$1.80
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-7.2%
$1.80 vs $1.94
Q4 '25
+36.1%
$2.26 vs $1.66
Q3 '25
+12.9%
$1.57 vs $1.39
Q2 '25
+14.9%
$1.16 vs $1.01
Q1 '25
-8.9%
$1.43 vs $1.57
Q4 '24
-4.5%
$1.07 vs $1.12
Q3 '24
-333.3%
$-1.82 vs $0.78
Q2 '24
-23.8%
$0.64 vs $0.84
Q1 '24
-8.6%
$1.06 vs $1.16
Q4 '23
+0.9%
$1.10 vs $1.09
Q3 '23
+19.3%
$0.99 vs $0.83
Q2 '23
-56.5%
$0.37 vs $0.85
No investor questions available.
Latest News
No news available